Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults
1 other identifier
interventional
328
1 country
14
Brief Summary
This is a first-in-human, Phase I/II, randomized, placebo-controlled, observer-blinded, age-escalating study to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with or without AS03 in healthy younger and older adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Feb 2021
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 3, 2021
CompletedFirst Submitted
Initial submission to the registry
February 10, 2021
CompletedFirst Posted
Study publicly available on registry
February 11, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 28, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2022
CompletedMay 10, 2022
May 1, 2022
6 months
February 10, 2021
May 9, 2022
Conditions
Outcome Measures
Primary Outcomes (13)
Occurrence of immediate systemic reactions - Stage 1
Through 30 minutes (2 hours for sentinel participants) post-vaccination
Occurrence of solicited local Adverse Events (AEs) during 7 days post each vaccination - Stage 1
Through 7 days post-vaccination
Occurrence of solicited systemic AEs during 7 days post each vaccination - Stage 1
Through 7 days post-vaccination
Occurrence of unsolicited AEs during 28 days post each vaccination - Stage 1
Through 28 days post-vaccination
Occurrence of Serious Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs) and Adverse Events of Special Interest (AESIs) during the whole study period - Stage 1
Through Day 0 to Day 365 post last vaccination
(Only in Sentinel group) Occurrence of out-of-normal range clinical laboratory test results (including change from baseline values) during 7 days post 1st vaccination - Stage 1
Through 7 days post 1st vaccination
GMT of IgG antibody to the SARS-CoV-2 RBD measured by Enzyme-linked Immunosorbent Assay (ELISA) - Stage 2
Through Day 365 post last vaccination
GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 2
Through Day 365 post last vaccination
Percentage of participants with ≥ 4-fold rise from baseline in ELISA IgG titer - Stage 2
Through Day 365 post last vaccination
GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 2
Through Day 365 post last vaccination
GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 2
Through Day 365 post last vaccination
Percentage of participants with ≥ 4-fold rise from baseline in pseudovirus and wild-type neutralizing antibody titer - Stage 2
Through Day 365 post last vaccination
Cell-mediated response for both Th1 and Th2 (e.g. INF-γ, IL-4 using Enzyme-linked ImmunoSpot (ELISpot) or other system) - Stage 2
Through Day 28 post last vaccination
Secondary Outcomes (12)
GMT of IgG antibody to the SARS-CoV-2 RBD measured by ELISA - Stage 1
Through Day 365 post last vaccination
GMFR of IgG antibody to the SARS-CoV-2 RBD from baseline measured by ELISA - Stage 1
Through Day 365 post last vaccination
Percentage of participants with ≥ 4-fold rise from baseline in ELISA IgG titer - Stage 1
Through Day 365 post last vaccination
GMT of neutralizing antibody to the SARS-CoV-2 measured by pseudovirus and wild-type virus neutralization assays - Stage 1
Through Day 365 post last vaccination
GMFR of neutralizing antibody to the SARS-CoV-2 from baseline measured by pseudovirus and wild-type virus neutralization assays - Stage 1
Through Day 365 post last vaccination
- +7 more secondary outcomes
Study Arms (10)
Test group 1 - Stage 1 Low dose-level Cohort
EXPERIMENTAL2 doses of GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 10μg/dose), 1 dose each on Days 0 and 28.
Test group 2 - Stage 1 Low dose-level Cohort
EXPERIMENTAL2 doses of GBP510 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
Placebo group - Stage 1 Low dose-level Cohort
PLACEBO COMPARATOR2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
Test group 3 - Stage 1 High dose-level Cohort
EXPERIMENTAL2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
Test group 4 - Stage 1 High dose-level Cohort
EXPERIMENTAL2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
Placebo group - Stage 1 High dose-level Cohort
PLACEBO COMPARATOR2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
Test group 1 - Stage 2
EXPERIMENTAL2 doses of GBP510 adjuvanted with AS03 (RBD 10μg/dose), 1 dose each on Days 0 and 28.
Test group 3 - Stage 2
EXPERIMENTAL2 doses of GBP510 adjuvanted with AS03 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
Test group 4 - Stage 2
EXPERIMENTAL2 doses of GBP510 (RBD 25μg/dose), 1 dose each on Days 0 and 28.
Placebo group - Stage 2
PLACEBO COMPARATOR2 doses of Placebo Saline, 1 dose each on Days 0 and 28.
Interventions
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Eligibility Criteria
You may qualify if:
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Age
- For Stage 1, participant must be 19 to 55 years of age inclusive, at the time of signing the informed consent.
- For Stage 2, participant must be 19 to 85 years of age inclusive, at the time of signing the informed consent
- Type of Participant and Disease Characteristics
- Participants who are healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and medical judgement of the investigator
- Participants who are able to attend all scheduled visits and comply with all study procedures.
- Weight
- Body mass index (BMI) within the range 18-30 kg/m2 at screening (inclusive)
- Sex and Contraceptive/Barrier Requirements
- Female participants of childbearing potential must agree to be heterosexually inactive, or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination
- Female participants with a negative urine or serum pregnancy test at screening
- Informed Consent
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
You may not qualify if:
- Participants are excluded from the study if any of the following criteria apply:
- Medical Conditions
- Any clinically significant respiratory symptoms (e.g. cough, sore throat), febrile illness (tympanic temperature \>38°C), or acute illness within 72 hours prior to the 1st study vaccination. A prospective participant should not be included until 72 hours after the condition has resolved.
- History of virologically-confirmed COVID-19 disease, or definite or suspected exposure to anyone known to have SARS-CoV-2 infection
- History of virologically-confirmed SARS or MERS disease
- History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease
- Any positive test results for hepatitis B, C, or HIV at screening
- History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion
- History of hypersensitivity and severe allergic reaction (e.g. anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention
- History of malignancy within 5 years prior to the 1st study vaccination
- Significant chronic illness that, in the opinion of the investigator, might increase risk of severe COVID-19, or interfere with the evaluation of the study objectives (e.g. asthma, chronic pulmonary disease, cardiovascular disease, chronic liver disease, diabetes mellitus, uncontrolled hypertension, renal disorders)
- History of, or planned surgery under general anesthesia from 1 year prior to the 1st study vaccination through the study period
- Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g. neurologic or psychiatric conditions)
- Female participants who are pregnant or breastfeeding
- (Only for Stage 1) Current smokers or a recent smoking history within 12 weeks prior to the 1st study vaccination. Occasional smokers who smoke up to 10 cigarettes per month may be allowed to participate at the investigator's discretion
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SK Bioscience Co., Ltd.lead
- Coalition for Epidemic Preparedness Innovationscollaborator
- GlaxoSmithKlinecollaborator
Study Sites (14)
Korea University Ansan Hospital
Ansan, South Korea
Dong-A University Hospital
Busan, South Korea
Kyungpook National University Chilgok Hospital
Daegu, South Korea
Kyungpook National University Hospital
Daegu, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Inha University Hospital
Incheon, South Korea
Korea University Anam Hospital
Seongnam-si, South Korea
Ewha Womans University Medical Center
Seoul, South Korea
Hallym University Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Ajou University Hospital
Suwon, South Korea
Wonju Severance Christian Hospital
Wŏnju, South Korea
Related Publications (2)
Song JY, Choi WS, Heo JY, Lee JS, Jung DS, Kim SW, Park KH, Eom JS, Jeong SJ, Lee J, Kwon KT, Choi HJ, Sohn JW, Kim YK, Noh JY, Kim WJ, Roman F, Ceregido MA, Solmi F, Philippot A, Walls AC, Carter L, Veesler D, King NP, Kim H, Ryu JH, Lee SJ, Park YW, Park HK, Cheong HJ. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinicalMedicine. 2022 Jul 22;51:101569. doi: 10.1016/j.eclinm.2022.101569. eCollection 2022 Sep.
PMID: 35879941DERIVEDArunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Roltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar MS, King NP, Veesler D, Pulendran B. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021 Jun;594(7862):253-258. doi: 10.1038/s41586-021-03530-2. Epub 2021 Apr 19.
PMID: 33873199DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hee Jin Cheong
Korea University Guro Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 10, 2021
First Posted
February 11, 2021
Study Start
February 3, 2021
Primary Completion
July 28, 2021
Study Completion
June 1, 2022
Last Updated
May 10, 2022
Record last verified: 2022-05